Scope Fluidics

Scope Fluidics Debt/EBITDA

The Total Debt to EBITDA Ratio of Scope Fluidics (SCP.WA) as of Oct 21, 2026 is -0.37. In the previous year, Total Debt to EBITDA Ratio was 0.17 — a change of -321.36% (lower).

Debt/EBITDA

-0.37

YoY

-321.36%

Last updated:

Total Debt to EBITDA Ratio of Scope Fluidics is 2025 -0.37 . Total Debt to EBITDA Ratio of Scope Fluidics was 2024 0.17 . It decreases by -321.36% lower compared to the previous year.

The Scope Fluidics Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2019
-0.18 PLN
Jan 1, 2020
-0.10 PLN
Jan 1, 2021
-2.46 PLN
Jan 1, 2022
0.02 PLN
Jan 1, 2023
-0.09 PLN
Jan 1, 2024
0.17 PLN
Jan 1, 2025
-0.37 PLN
The Scope Fluidics Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.37-321.36%
0.17-291.48%
-0.09-545.84%
0.02-100.80%
-2.46+2,258.37%
-0.10-41.22%
-0.18—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scope Fluidics Stock analysis

What does Scope Fluidics do? Scope Fluidics SA generates revenue through the development and sale of disposable microfluidic systems for blood sample collection and reagent storage, targeting diagnostic and med-tech applications. The company's PCR ONE system detects bacterial and viral pathogens, while the BacterOMIC system provides data on bacterial susceptibility to antibiotics and resistance mechanisms. It offers laboratory access, workshops, and administrative services, including financing, to support its projects. Key clients include doctors, medical personnel, project managers, engineers, and academics who collaborate on its diagnostic solutions. The firm monetizes its R&D focus by providing specialized diagnostic tools and infrastructure services. Its products are designed for healthcare professionals and research institutions requiring advanced pathogen detection and antibiotic resistance analysis. By delivering both hardware systems like PCR ONE and BacterOMIC, and supporting services such as lab access and financing, Scope Fluidics SA serves the healthcare sector with tailored solutions for diagnostics and med-tech innovation. Scope Fluidics SA's revenue streams are derived from the sale of microfluidic systems, project support services, and access to its facilities. The company's target segments include medical professionals, researchers, and institutions engaged in diagnostic testing and antibiotic resistance studies. Its offerings combine hardware, software-free diagnostic tools, and collaborative infrastructure to address specific healthcare challenges in pathogen detection and treatment planning. Scope Fluidics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scope Fluidics stock

Total Debt to EBITDA Ratio of Scope Fluidics is -0.37 in 2025.

Total Debt to EBITDA Ratio of Scope Fluidics changed from 0.17 to -0.37, representing a -321.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Scope Fluidics since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Scope Fluidics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Scope Fluidics

All Key Metrics — Scope Fluidics